improvement efficacy of influenza nanovaccine in combination with hemokinin-1 molecular adjuvant

Background: h9n2 avian influenza viruses have the potential to become the next human pandemic threat and next generation vaccine technologies are needed. current studies introduce nanoparticles as a proper vaccine delivery vehicle for induction of protective immunity. in this study, the efficacy of chitosan nanoparticle-based h9n2 influenza vaccine with and without hemokinin-1 (hk-1) as a molecular adjuvant to induce protective immunity against the virus was examined. methods: the h9n2 antigen was prepared in mdck cells and inactivated with formalin. the inactivated antigen alone and in combination with hk-1 was encapsulated into chitosan nanoparticles. groups of balb/c mice received chitosan nanoparticle- based h9n2 antigen alone or in combination with hk-1 in a prime/boost platform via eye drop method. to evaluate the efficacy of the adjuvanted-nanovaccine candidate, systemic antibody responses were compared among the groups of animals. results: serological analysis indicated that mice receiving the hk-1/h9n2 nanoparticles formulation induced higher antibody titers that were sustained until the end of experiment. however, in the immunized mice, influenza specific antibody titers were comparable to that in the animals which were immunized either with inactivated antigen alone or the h9n2 nanoparticles without hk-1 adjuvant. conclusion: the data demonstrate the synergy between hk-1 as an adjuvant and chitosan nanoparticles as a delivery antigen/adjuvant carrier in the improvement of influenza immune responses.